These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 34750487)

  • 1. Incorporation of apolipoprotein E into HBV-HCV subviral envelope particles to improve the hepatitis vaccine strategy.
    Gomez-Escobar E; Burlaud-Gaillard J; Visdeloup C; Ribeiro E Silva A; Coutant P; Roingeard P; Beaumont E
    Sci Rep; 2021 Nov; 11(1):21856. PubMed ID: 34750487
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chimeric hepatitis B virus/hepatitis C virus envelope proteins elicit broadly neutralizing antibodies and constitute a potential bivalent prophylactic vaccine.
    Beaumont E; Patient R; Hourioux C; Dimier-Poisson I; Roingeard P
    Hepatology; 2013 Apr; 57(4):1303-13. PubMed ID: 23150224
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunizations with chimeric hepatitis B virus-like particles to induce potential anti-hepatitis C virus neutralizing antibodies.
    Vietheer PT; Boo I; Drummer HE; Netter HJ
    Antivir Ther; 2007; 12(4):477-87. PubMed ID: 17668556
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Native Folding of a Recombinant gpE1/gpE2 Heterodimer Vaccine Antigen from a Precursor Protein Fused with Fc IgG.
    Logan M; Law J; Wong JAJ; Hockman D; Landi A; Chen C; Crawford K; Kundu J; Baldwin L; Johnson J; Dahiya A; LaChance G; Marcotrigiano J; Law M; Foung S; Tyrrell L; Houghton M
    J Virol; 2017 Jan; 91(1):. PubMed ID: 27795422
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neutralization effects of antibody elicited by chimeric HBV S antigen viral-like particles presenting HCV neutralization epitopes.
    Wei S; Lei Y; Yang J; Wang X; Shu F; Wei X; Lin F; Li B; Cui Y; Zhang H; Wei S
    Vaccine; 2018 Apr; 36(17):2273-2281. PubMed ID: 29576303
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chimeric hepatitis B virus (HBV)/hepatitis C virus (HCV) subviral envelope particles induce efficient anti-HCV antibody production in animals pre-immunized with HBV vaccine.
    Beaumont E; Roingeard P
    Vaccine; 2015 Feb; 33(8):973-6. PubMed ID: 25596457
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel adeno‑associated virus‑based genetic vaccines encoding hepatitis C virus E2 glycoprotein elicit humoral immune responses in mice.
    Zhu F; Wang Y; Xu Z; Qu H; Zhang H; Niu L; Xue H; Jing D; He H
    Mol Med Rep; 2019 Feb; 19(2):1016-1023. PubMed ID: 30569131
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hepatitis C virus hypervariable region 1 variants presented on hepatitis B virus capsid-like particles induce cross-neutralizing antibodies.
    Lange M; Fiedler M; Bankwitz D; Osburn W; Viazov S; Brovko O; Zekri AR; Khudyakov Y; Nassal M; Pumpens P; Pietschmann T; Timm J; Roggendorf M; Walker A
    PLoS One; 2014; 9(7):e102235. PubMed ID: 25014219
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Recombinant Hepatitis C Virus Genotype 1a E1/E2 Envelope Glycoprotein Vaccine Elicits Antibodies That Differentially Neutralize Closely Related 2a Strains through Interactions of the N-Terminal Hypervariable Region 1 of E2 with Scavenger Receptor B1.
    Johnson J; Freedman H; Logan M; Wong JAJ; Hockman D; Chen C; He J; Beard MR; Eyre NS; Baumert TF; Tyrrell DL; Law JLM; Houghton M
    J Virol; 2019 Nov; 93(22):. PubMed ID: 31462563
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antibody Responses to Immunization With HCV Envelope Glycoproteins as a Baseline for B-Cell-Based Vaccine Development.
    Chen F; Nagy K; Chavez D; Willis S; McBride R; Giang E; Honda A; Bukh J; Ordoukhanian P; Zhu J; Frey S; Lanford R; Law M
    Gastroenterology; 2020 Mar; 158(4):1058-1071.e6. PubMed ID: 31809725
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Altered Glycosylation Patterns Increase Immunogenicity of a Subunit Hepatitis C Virus Vaccine, Inducing Neutralizing Antibodies Which Confer Protection in Mice.
    Li D; von Schaewen M; Wang X; Tao W; Zhang Y; Li L; Heller B; Hrebikova G; Deng Q; Ploss A; Zhong J; Huang Z
    J Virol; 2016 Dec; 90(23):10486-10498. PubMed ID: 27630242
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression, purification, immunological characterization and application of Escherichia coli-derived hepatitis C virus E2 proteins.
    Liu J; Zhu L; Zhang X; Lu M; Kong Y; Wang Y; Li G
    Biotechnol Appl Biochem; 2001 Oct; 34(2):109-19. PubMed ID: 11592917
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of the E2 Hypervariable Region (HVR1) in the Immunogenicity of a Recombinant Hepatitis C Virus Vaccine.
    Law JLM; Logan M; Wong J; Kundu J; Hockman D; Landi A; Chen C; Crawford K; Wininger M; Johnson J; Mesa Prince C; Dudek E; Mehta N; Tyrrell DL; Houghton M
    J Virol; 2018 Jun; 92(11):. PubMed ID: 29540595
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neutralizing antibodies induced by cell culture-derived hepatitis C virus protect against infection in mice.
    Akazawa D; Moriyama M; Yokokawa H; Omi N; Watanabe N; Date T; Morikawa K; Aizaki H; Ishii K; Kato T; Mochizuki H; Nakamura N; Wakita T
    Gastroenterology; 2013 Aug; 145(2):447-55.e1-4. PubMed ID: 23673355
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oral immunization with attenuated Salmonella carrying a co-expression plasmid encoding the core and E2 proteins of hepatitis C virus capable of inducing cellular immune responses and neutralizing antibodies in mice.
    Cao J; Chen Z; Ren Y; Luo Y; Cao M; Lu W; Zhao P; Qi Z
    Vaccine; 2011 May; 29(20):3714-23. PubMed ID: 21396407
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Hepatitis C Virus DNA Vaccine Encoding a Secreted, Oligomerized Form of Envelope Proteins Is Highly Immunogenic and Elicits Neutralizing Antibodies in Vaccinated Mice.
    Masavuli MG; Wijesundara DK; Underwood A; Christiansen D; Earnest-Silveira L; Bull R; Torresi J; Gowans EJ; Grubor-Bauk B
    Front Immunol; 2019; 10():1145. PubMed ID: 31178869
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antigenicity and immunogenicity of novel chimeric hepatitis B surface antigen particles with exposed hepatitis C virus epitopes.
    Netter HJ; Macnaughton TB; Woo WP; Tindle R; Gowans EJ
    J Virol; 2001 Mar; 75(5):2130-41. PubMed ID: 11160717
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunization with a synthetic consensus hepatitis C virus E2 glycoprotein ectodomain elicits virus-neutralizing antibodies.
    Tarr AW; Backx M; Hamed MR; Urbanowicz RA; McClure CP; Brown RJP; Ball JK
    Antiviral Res; 2018 Dec; 160():25-37. PubMed ID: 30217650
    [TBL] [Abstract][Full Text] [Related]  

  • 19. DNA immunization with fusion genes encoding different regions of hepatitis C virus E2 fused to the gene for hepatitis B surface antigen elicits immune responses to both HCV and HBV.
    Jin J; Yang JY; Liu J; Kong YY; Wang Y; Li GD
    World J Gastroenterol; 2002 Jun; 8(3):505-10. PubMed ID: 12046080
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design of a native-like secreted form of the hepatitis C virus E1E2 heterodimer.
    Guest JD; Wang R; Elkholy KH; Chagas A; Chao KL; Cleveland TE; Kim YC; Keck ZY; Marin A; Yunus AS; Mariuzza RA; Andrianov AK; Toth EA; Foung SKH; Pierce BG; Fuerst TR
    Proc Natl Acad Sci U S A; 2021 Jan; 118(3):. PubMed ID: 33431677
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.